Newest studies

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis

66/100 ✓ Peer-reviewed Caregiving The American journal of psychiatry

Key finding: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. +2 more findings

• Other Dementias

Full summary, score breakdown and related studies → Original source

Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment

56/100 ✓ Peer-reviewed Prevention and risk Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Mild behavioral impairment (MBI) has been proposed as a diagnostic construct aimed to identify patients with an increased risk of developing dementia, but who may or may not have cognitive symptoms. +1 more finding

• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

The “Rising Tide” of dementia in Canada

34/100 ✓ Peer-reviewed Health systems and care delivery Canadian Pharmacists Journal / Revue des Pharmaciens du Canada

Key finding: The prevalence of dementia was estimated at 44.4 million people worldwide in 2013, and in the absence of any significant new scientific discovery, prevalence rates are estimated to increase to 75.6 million in 2030 and 135.5 million in 2050.1 Alzheimer’s disease is the most common irreversible form of dementia. +1 more finding

Full summary, score breakdown and related studies → Original source

Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings

52/100 ✓ Peer-reviewed Long-term cohort studies Neurology

Key finding: We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration

48/100 ✓ Peer-reviewed Lewy body dementia Neurobiology of disease

Key finding: Previous studies demonstrate that intrastriatal injections of fibrillar alpha-synuclein (α-syn) into mice induce Parkinson's disease (PD)-like Lewy body (LB) pathology formed by aggregated α-syn in anatomically interconnected regions and significant nigrostriatal degeneration. +4 more findings

• Brain Biology
• Other Dementias

Full summary, score breakdown and related studies → Original source

Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study

57/100 ✓ Peer-reviewed Drug development PLoS medicine

Key finding: Inherited lifetime exposure to higher SBP is associated with lower AD risk. +4 more findings

• Risk Factors
• Prevention

Full summary, score breakdown and related studies → Original source

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

47/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. +2 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Aberrant insulin signaling in Alzheimer's disease: current knowledge

46/100 ✓ Peer-reviewed Risk factors Frontiers in neuroscience

Key finding: Recent studies suggest that AD may be linked to brain insulin resistance and patients with diabetes have an increased risk of developing AD compared to healthy individuals. +1 more finding

• Risk Factors
• Brain Biology

Full summary, score breakdown and related studies → Original source

Identification of PSEN2 mutation p.N141I in Argentine pedigrees with early-onset familial Alzheimer's disease

45/100 ✓ Peer-reviewed Risk genes beyond APOE Neurobiology of aging

Key finding: The p.N141I mutation was identified in all affected subjects and was associated with prominent early onset, rapidly progressive dementia, neurologic, and behavioral symptoms.

• Genetics

Full summary, score breakdown and related studies → Original source

The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial

69/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Vascular cognitive impairment without dementia is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. +3 more findings

• Other Dementias
• Clinical Trials

Full summary, score breakdown and related studies → Original source

MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options

45/100 ✓ Peer-reviewed Risk factors Molecular genetics and metabolism

Key finding: The most common mutation associated with MELAS syndrome is the m.3243A>G mutation in the MT-TL1 gene encoding the mitochondrial tRNA(Leu(UUR)). +3 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

MIND diet slows cognitive decline with aging

62/100 ✓ Peer-reviewed Risk factors Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Replication of these findings in a dietary intervention trial would be required to verify its relevance to brain health. +1 more finding

• Lifestyle

Full summary, score breakdown and related studies → Original source

Sleep duration, cognitive decline, and dementia risk in older women

68/100 ✓ Peer-reviewed Prevention and risk Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: In older women, habitual sleep duration predicts the future risk for cognitive impairments including dementia, independent of vascular risk factors.

• Risk Factors
• Lifestyle

Full summary, score breakdown and related studies → Original source

The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B

45/100 ✓ Peer-reviewed Down syndrome and Alzheimer's Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Factors unrelated to aging may drive an increase in deposition during early Alzheimer's disease pathogenesis.

• Down Syndrome

Full summary, score breakdown and related studies → Original source

Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury

44/100 ✓ Peer-reviewed Inflammation and the immune system British journal of pharmacology

Key finding: Described initially in boxers and currently recognized across high contact sports, the association between repeated concussion (mild TBI) and progressive neuropsychiatric abnormalities has recently received widespread attention, and has been termed chronic traumatic encephalopathy. +3 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

"Down syndrome: an insight of the disease"

40/100 ✓ Peer-reviewed Down syndrome and Alzheimer's Journal of biomedical science

Key finding: DS is associated with number of phenotypes including congenital heart defects, leukemia, Alzeihmer's disease, Hirschsprung disease etc.

• Down Syndrome

Full summary, score breakdown and related studies → Original source

The epigenetics of aging and neurodegeneration

36/100 ✓ Peer-reviewed Genetics Progress in neurobiology

Key finding: Epigenetic regulation covers multiple levels of gene expression; from direct modifications of the DNA and histone tails, regulating the level of transcription, to interactions with messenger RNAs, regulating the level of translation. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Relationship Between Type 2 Diabetes Mellitus and Cognitive Change in a Multiethnic Elderly Cohort

59/100 ✓ Peer-reviewed Disparities Journal of the American Geriatrics Society

Key finding: The rate of cognitive change in elderly persons with and without diabetes mellitus is similar, although cognitive performance is poorer in persons with diabetes mellitus. +2 more findings

• Risk Factors
• Health Equity

Full summary, score breakdown and related studies → Original source

α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

41/100 ✓ Peer-reviewed Vascular contributions Nature

Key finding: Our results demonstrate that distinct α-SYN strains display differential seeding capacities, inducing strain-specific pathology and neurotoxic phenotypes.

• Other Dementias

Full summary, score breakdown and related studies → Original source

Achieving consensus and controversy around applicability of palliative care to dementia

36/100 ✓ Peer-reviewed End-of-life care International psychogeriatrics

Key finding: Benefits of palliative care in dementia are acknowledged by experts worldwide, but there is some controversy around its early introduction. +3 more findings

• End-of-Life Care

Full summary, score breakdown and related studies → Original source

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

43/100 ✓ Peer-reviewed Prevention trials Molecular aspects of medicine

Key finding: Evidence suggests that cognitive training focused on remediation and physical exercise interventions may promote small improvements in selected cognitive abilities. +1 more finding

• Early Stage

Full summary, score breakdown and related studies → Original source

Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

62/100 ✓ Peer-reviewed Getting a diagnosis Neurology

Key finding: Levels of autolysosomal proteins in neurally derived blood exosomes distinguish patients with AD from case controls and appear to reflect the pathology of AD up to 10 years before clinical onset. +3 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

40/100 ✓ Peer-reviewed Drug development Scientific reports

Key finding: However, it is not known whether microglia play a similar role in the clearance of tau, the major component of neurofibrillary tangles (NFTs). +4 more findings

• Treatments
• Brain Biology

Full summary, score breakdown and related studies → Original source

The economic evidence for advance care planning: Systematic review of evidence

64/100 ✓ Peer-reviewed End-of-life care Palliative medicine

Key finding: There is need for clearer articulation of the likely mechanisms by which advance care planning can lead to reduced care costs or improved cost-effectiveness, particularly for people who retain capacity. +2 more findings

• End-of-Life Care
• Policy

Full summary, score breakdown and related studies → Original source

Proteomic analysis of host brain components that bind to infectious particles in Creutzfeldt-Jakob disease

31/100 ✓ Peer-reviewed Biomarkers Proteomics

Key finding: More than 98 proteins were differentially regulated, and 56 FU-CJD exclusive proteins were revealed after PrP, GFAP, C1q, ApoE, and other late pathologic response proteins were removed. +1 more finding

• Brain Biology

Full summary, score breakdown and related studies → Original source